


Arguments/Remarks

Claims 1-5 and 9 are pending in the present application. Claims 3 and 9 have been cancelled as being directed to non-elected subject matter. Claim 4 has been amended to eliminate the non-elected subject matter. Applicants reserve the right to file one or more divisional applications which claim the non-elected subject matter.

Applicants elect the subject matter of Group I (Claims 1-5) drawn to a compound of formula I wherein R1 is chemical moiety (a) without traverse. Applicants provisionally elect the compound of Example 2 (illustrated below) as the species upon which the Examiner may begin examination on the merits.

(1S,3S,10R,11S,12S,16R)-11-Hydroxy-8,8,10,12,16-pentamethyl-3-[(E)-1-methyl-2-(2-methyl-thiazol-4-yl)-vinyl]-4,17-dioxo-bicyclo[14.1.0]heptadecane-5,9-dione.



Applicants reserve the right to rejoinder of all compounds that fall within the scope of the current claims in addition to the provisionally elected species.

Respectfully submitted,

Novartis Institutes for BioMedical Research, Inc.
220 Massachusetts Avenue
Cambridge, MA 02139
(617) 671-5098


Arlene K. Musser
Attorney for Applicants
Reg. No. 37,895

Date: 19 November 2009